Windtree Therapeutics Announces Financial Results for Quarter Ended September 30, 2024

Windtree Therapeutics, Inc. recently disclosed its financial performance in a press release for the quarter ending September 30, 2024. The company, based in Delaware, issued the announcement on November 27, 2024. In the statement, Windtree Therapeutics highlighted its financial results for the specified period. The full details can be accessed in Exhibit 99.1 attached to the Current Report on Form 8-K.

This information, including the press release referenced as Exhibit 99.1, is being furnished with this report. It is important to note that this data is provided for informational purposes and is not considered “filed” under the Securities Exchange Act of 1934. As a result, it does not bear the liabilities related to that section nor is it deemed to be incorporated by reference in any SEC filings, unless explicitly stated.

Additionally, on November 21, 2024, Windtree Therapeutics received a notification from the Nasdaq Listing Qualifications Staff regarding a delay in filing its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024. Consequently, the company was deemed non-compliant with Nasdaq Listing Rule 5250(c)(1), which necessitates timely filing of all mandatory financial reports with the SEC. However, following the filing of the Form 10-Q on November 26, 2024, and subsequent correspondence received on November 27, 2024, from Nasdaq confirming compliance with the rule, the matter has now been closed.

As part of the filing, Windtree Therapeutics disclosed the inclusion of certain exhibits. These exhibits include the press release detailing the financial outcome for the quarter that ended September 30, 2024, as well as an Interactive Data File embedded within the Inline XBRL document, marked as Exhibit 104.

Windtree Therapeutics concluded the report with requisite signatures, certifying the accuracy of the information presented. The report was signed on behalf of the company by Craig E. Fraser, the President, and Chief Executive Officer of Windtree Therapeutics, on November 27, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Windtree Therapeutics’s 8K filing here.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.